Terminated PHASE3 INTERVENTIONAL 2-arm NCT01187888

Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy (PROSPERA)

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)

Sponsor: Ludwig-Maximilians - University of Munich

Conditions Progressive Supranuclear Palsy

Interventions Rasagiline Sugar pill

Updated 10 times since 2017 Last updated: Apr 23, 2013 Started: Jan 31, 2010 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available for the study(pre-treatm.with Rasagiline=exclusion criterion

Other terminated trials from Ludwig-Maximilians - University of Munich

See all terminations from Ludwig-Maximilians - University of Munich

Other Progressive Supranuclear Palsy trials with similar outcome

Browse all Progressive Supranuclear Palsy trials

Listed as NCT01187888, this PHASE3 trial focuses on Progressive Supranuclear Palsy and remains terminated or withdrawn. Sponsored by Ludwig-Maximilians - University of Munich, it has been updated 10 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2022 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jan 2022 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE3

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ludwig-Maximilians - University of Munich
Prof. Dr. Stefan Lorenzl
Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Ludwig-Maximilians - University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• München, Germany